| Literature DB >> 33243167 |
Fran Biggin1, Hedley C A Emsley2,3, Jo Knight1.
Abstract
BACKGROUND: This review focuses on neurology research which uses routinely collected data. The number of such studies is growing alongside the expansion of data collection. We aim to gain a broad picture of the scope of how routine healthcare data have been utilised.Entities:
Keywords: Electronic health record; Neurology; Routinely collected data
Mesh:
Year: 2020 PMID: 33243167 PMCID: PMC7694309 DOI: 10.1186/s12883-020-01993-w
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Fig. 1Flow chart showing study selection procedure
Fig. 2Neurology studies as a percentage of all medical studies. A graph of neurology papers as a percentage of all papers relating to the use of EHRs and Routinely Collected Data each year retrieved from a PubMed search
Overview of study characteristics
| Data Item | Category | Full Articles ( | Abstract Only ( |
|---|---|---|---|
| Neurological Condition | Multiple Conditions | 4 (1·9) | 7 (3·9) |
| Single Conditions: | |||
| Multiple Sclerosis | 61 (29·5) | 78 (43·6) | |
| Epilepsy/Seizure | 42 (20·3) | 21 (11·7) | |
| Parkinson’s Disease | 15 (7·2) | 14 (7·8) | |
| Headache (all) | 18 (8·7) | 12 (6·7) | |
| Migraine only | 10 (4·8) | 6 (3·4) | |
| Neurodegenerative Disorders | 6 (2·9) | 2 (1·1) | |
| Neuromuscular Disorders | 5 (2·4) | 4 (2·2) | |
| Other | 56 (27·1) | 41 (22·9) | |
| Statistical Methodology | Descriptive | 127 (61·3) | 116 (64·8) |
| Regression | 35 (16·9) | 33 (18·4) | |
| Survival Analysis | 12 (5·8) | 8 (4·5) | |
| Administrative Data Algorithm | 9 (4·3) | 6 (3·3) | |
| Machine Learning | 5 (2·4) | 2 (1·1) | |
| NLP | 5 (2·4) | 5 (2·8) | |
| Propensity Scoring | 4 (1·9) | 4 (2·2) | |
| ANOVA | 3 (1·4) | 1 (0·6) | |
| Other | 7 (3·4) | 4 (2·2) | |
| Study Objective | Characterisation of a clinical population | 46 (22·2) | 44 (24·6) |
| Risk Factors | 42 (20·3) | 31 (17·3) | |
| Drug Effectiveness | 26 (12·6) | 15 (8·3) | |
| Prediction | 18 (8·7) | 13 (7·3) | |
| Healthcare Utilisation | 13 (6·3) | 9 (5·0) | |
| Diagnosis Validity | 13 (6·3) | 5 (2·8) | |
| Prevalence | 9 (4·3) | 7 (3·9) | |
| Drug Safety | 9 (4·3) | 5 (2·8) | |
| Drug Adherence | 8 (3·9) | 8 (4·5) | |
| Other | 24 (11·6) | 42 (23·5) | |
| Data Type | Hospital Data | 91 (44·0) | 66 (36·9) |
| Claims Data | 22 (10·6) | 44 (24·6) | |
| Clinic Data | 30 (14·5) | 28 (15·6) | |
| Multicentre Data | 23 (11·1) | 21 (11·7) | |
| Veterans or Military Data | 13 (6·3) | 11 (6·2) | |
| Primary Care Data | 16 (7·7) | 2 (1·1) | |
| Pharmaceutical Data | 3 (1·5) | 6 (3·4) | |
| Other | 9 (4·3) | 1 (0·6) | |
| Location | USA | 112 (54·1) | 127 (70·9) |
| Europe | 54 (26·1) | 30 (16·8) | |
| Rest of World | 41 (19·8) | 22 (12·3) | |
Fig. 3Visualisation of study characteristics. A breakdown of 3 of the variables extracted from each study. Panel a shows the percentage of studies focused on each neurological condition, b shows the percentage of studies using different statistical methodologies and c shows study objectives